MMP-9 is a Potential Prognostic Marker of Left Ventricular Remodeling in Patients with Coronary Artery Disease
- 1 Department of Cardiosurgery, Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
- 2 Institute for Atherosclerosis Research, Moscow, Russia
- 3 National Medical Research Center of Cardiology Named After Academician E. I. Chazov, Moscow, Russia
- 4 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Petrovsky National Research Centre of Surgery, Moscow, Russia
- 5 Vascular Surgery Department, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russia
Abstract
Matrix Metalloproteinase-9 (MMP-9) emerges as a promising prognostic marker for assessing left ventricular remodeling in patients with coronary artery disease, particularly in the context of Ischemic Heart Disease (IHD) complicated by left ventricular aneurysm. In this study, we conducted two parallel investigations to explore the prognostic significance of MMP-9 in patients with multivessel coronary artery disease undergoing left ventricular reconstruction via coronary artery bypass grafting. Two distinct cohorts were examined in this research. The first group underwent analysis of MMP-9 levels in biopsies of the left ventricular myocardium, focusing on paracollagen type 4-MMP-9. The second group had their blood plasma MMP-9 concentrations scrutinized. The study primarily aimed to assess the predictive value of MMP-9 in determining postoperative prognoses and treatment outcomes. Our initial findings from the biopsy analysis revealed a significant association (p = 0.001) between para-collagen type 4-MMP-9 levels and unfavorable prognoses in the early postoperative period. Furthermore, monitoring MMP-9 levels in blood plasma for 5 years indicated a correlation between elevated MMP-9 concentrations and ongoing ischemic changes post-myocardial revascularization, suggesting a progression toward congestive heart failure. Notably, a substantial decrease (p = 0.002) in MMP-9 concentration was observed in patients post-surgery, underscoring the positive impact of myocardial revascularization on MMP-9 levels. The research underscores the potential of MMP-9 as a valuable marker for predicting adverse outcomes post-myocardial revascularization and myocardial remodeling surgery. Elevated MMP-9 levels in plasma signify a risk of CHF progression, while decreased levels post-surgery point towards the benefits of revascularization interventions. This study offers critical insights into leveraging MMP-9 as a prognostic tool in guiding optimal treatment strategies for patients with coronary artery disease and left ventricular remodeling, emphasizing its relevance in enhancing patient care and clinical decision-making
DOI: https://doi.org/10.3844/ojbsci.2024.720.727
Copyright: © 2024 Mikhail Aleksandrovich Popov, Anastasia Vladimirovna Poznyak, Dmitry Valerievich Shumakov, Dmitry Igorevich Zybin, Natalia Mikhailovna Kashirina, Liudmila Nikolaevna Lipatova, Mikhail Mikhailovich Peklo, Pavel Nikolaevich Rutkevich, Elena Vadimovna Yanushevskaya, Elizaveta Mikhailovna Pleshko, Victor Yurievich Glanz, Vasily Nikolaevich Sukhorukov, Dmitry Felixovich Beloyartsev and Alexander Nikolaevich Orekhov. This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- 1,045 Views
- 496 Downloads
- 0 Citations
Download
Keywords
- Left Ventricular Aneurysm
- Matrix Metalloproteinase 9
- Chronic Heart Failure
- Atherosclerosis